http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0620415-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-38 |
| filingDate | 2006-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d8920514d4372f71bbee4c487411762 |
| publicationDate | 2011-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0620415-A2 |
| titleOfInvention | pharmaceutically and pharmacologically acceptable salts and salts thereof, and enantiomers of the compound and salts thereof, pharmaceutical composition, and, use of a compound optionally in combination with a gabab receptor agonist, and methods for treating disease, a disorder, and syndrome |
| abstract | PHARMACEUTICALLY AND PHARMACOLOGICALLY ACCEPTABLE COMPOUNDS AND SALTS OF THE SAME, AND COMPONENTS AND SALTS OF THE SAME, PHARMACEUTICAL COMPOSITION, AND, USE OF AN OPTIONAL COMPOUND IN COMPONENT WITH THE AGAINST THE GATHING, RECEIVER, THERAPY, ~ , DISTURBANCE, AND SYNDROME. The present invention relates to new pyrazole compounds having a positive allosteric GABA ~ B ~ (GBR) modulating effect, methods for the preparation of said compounds and their use, optionally in combination with a GABA ~ B agonist ~, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastro-esophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS). The compounds are represented by the general formula (I) in which R ^ 1 ^, R ^ 2 ^, R ^ 3 ^, and Y are as defined in the description. For example, R4.14 may be hydrogen or alkyl, R2.24 may be hydrogen or alkyl, R4.34 may be alkoxy and Y may be a substituent attached to a carbonylamino containing an aryl group. |
| priorityDate | 2005-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 103.